Cost effectiveness of a survivorship care plan for breast cancer survivors

Journal of Oncology Practice

Volumn 10, Issue 2, 2014, Pages

  Coyle, Doug ^a   Grunfeld, Eva ^a   Coyle, Kathryn ^a   Pond, Gregory ^a   Julian, Jim A ^a   Levine, Mark N ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SURVIVOR; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; NURSE; PRACTICE GUIDELINE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SURVIVORSHIP CARE PLAN; TREATMENT OUTCOME; BREAST TUMOR; CLINICAL TRIAL (TOPIC); FEMALE; HEALTH CARE SURVEY; PATIENT CARE PLANNING; PRIMARY HEALTH CARE; QUALITATIVE RESEARCH; QUESTIONNAIRE; SURVIVOR;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE SURVEYS; HUMANS; PATIENT CARE PLANNING; PHYSICIANS, PRIMARY CARE; PRIMARY HEALTH CARE; QUALITATIVE RESEARCH; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SURVIVORS;

EID: 84904509889     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2013.001142     Document Type: Article

References (31)

1. Hewitt M, Greenfield S, Stovall E: From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC, National Academies Press, 2006
2. Erikson C, Salsberg E, Forte G, et al: Future supply and demand for oncologists: Challenges to assuring access to oncology services. J Oncol Pract 3:79-86, 2007 (Pubitemid 351593695)
3. Grunfeld E, Levine MN, Julian JA, et al: Randomized trial of long-term follow- up for early stage breast cancer: A comparison of family physician versus specialist care. J Clin Oncol 24:848-855, 2006 (Pubitemid 46638835)
4. Grunfeld E, Julian JA, Pond G, et al: Evaluating survivorship care plans: Results of a randomized clinical trial with breast cancer patients. J Clin Oncol 29:4755-4762, 2011
5. Canadian Cancer Society: Canadian cancer statistics 2013. Toronto, Ontario, Canada, Canadian Cancer Society, 2013
6. U.S. Cancer Statistics Working Group: United States cancer statistics (USCS): 1999-2009 incidence and mortality Web-based report. www.cdc.gov/uscs
7. Earle CC, Coyle D, Evans WK: Cost-effectiveness analysis in oncology. Ann Oncol 9:475-482, 1998 (Pubitemid 28270633)
8. Canadian Agency for Drugs and Technologies: Guidelines for Economic Evaluation of Pharmaceuticals in Canada (ed 3). Ottawa, Ontario, Canada, Canadian Agency for Drugs and Technologies, 2006
9. Lin DY: Linear regression analysis of censored medical costs. Biostatistics 1:35-47, 2000
10. Brazier JE, Harper R, Jones NM, et al: Validating the SF-36 Health Survey Questionnaire: New outcome measure for primary care. BMJ 305:160-164, 1992
11. Kharroubi SA, Brazier JE, Roberts J, et al: Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ 26:597-612, 2007 (Pubitemid 46562487)
12. Kharroubi S, O'Hagan A, Brazier J: Estimating utilities from individual health preference data: A nonparametric Bayesian method. Appl Stat 54:879-895, 2005 (Pubitemid 41524360)
13. Walker M, de Jonge PV, Doyle S, et al: Elicitation of UK health utilities in primary, recurrent and metastatic breast cancer. Ann Oncol 17:81-82, 2006
14. Bank of Canada: Inflation calculator. www.bankofcanada.ca/rates/related/ inflation-calculator/
15. Ontario Ministry of Health and Long-Term Care: Schedule of benefits for laboratory services. www.health.gov.on.ca/english/providers/program/ohip/sob/ lab/lab-mn.html
16. Telford JJ, Levy AR, Sambrook JC, et al: The cost-effectiveness of screening for colorectal cancer. CMAJ 7182:1307-1313, 2010
17. Coburn N, Przybysz R, Law C, et al: Utilization of CT and MRI scanning among cancer patients in Ontario, 1993-2002. ICES Investigative Report. www.ices.on.ca/file/Utilization-of-CT-and-MRI-Scanning.pdf
18. Ontario Ministry of Health and Long-Term Care: Schedule of benefits for physician services under the Health Insurance Act. www.health.gov.on.ca/english/ providers/program/ohip/sob/physserv/physserv-mn.html
19. Coyle D, O'Grady K, Julian JA, et al: Cost effectiveness of strategies for the long term follow up for early stage breast cancer. Med Decis Making 27:E20, 2007
20. Canadian Automobile Association: Driving costs 2010 edition. www.caa.ca/documents/CAA-Driving-Costs-Brochure-2010.pdf
21. Koopmanschap MA, Rutten FF, van Ineveld BM, et al: The friction cost method for measuring indirect costs of disease. J Health Econ 14:171-189, 1995
22. Rocchi A, Verma S: Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 14:917-927, 2006
23. Campbell MK, Torgerson DJ: Bootstrapping: Estimating confidence intervals for cost-effectiveness ratios. QJM 92:177-182, 1999
24. Briggs AH: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479-500, 2000
25. Earle CC, Ganz PA: Cancer survivorship care: Don't let the perfect be the enemy of the good. J Clin Oncol 30:3764-3768, 2012
26. McCabe MS, Faithfull S, Makin W, et al: Survivorship programs and care planning. Cancer 119:2179-2186, 2013 (suppl 11)
27. Fryback DG, Palta M, Cherepanov D, et al: Comparison of 5 health-related quality-of-life indexes using item response theory analysis. Med Decis Making 30:5-15, 2010
28. Bharmal M, Thomas J 3rd: Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9:262-271, 2006 (Pubitemid 44126781)
29. Sculpher MJ, Claxton K, Drummond M, et al: Whither trial based economic evaluation for health care decision making? Health Econ 15:677-687, 2006 (Pubitemid 44057239)
30. Evans WK, Coyle D, Gafni A, et al: Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis. Chronic Dis Can 24:102-107, 2003 (Pubitemid 38155548)
31. Coyle D, Lee KM: The problem of protocol driven costs in pharmacoeconomic analysis. Pharmacoeconomics 14:357-363, 1998 (Pubitemid 28455684)